JNJ logo

JNJ
Johnson & Johnson

48,432
Mkt Cap
$704.99B
Volume
8.13M
52W High
$246.35
52W Low
$141.50
PE Ratio
22.03
JNJ Fundamentals
Price
$244.99
Prev Close
$243.33
Open
$243.24
50D MA
$217.50
Beta
0.07
Avg. Volume
9.57M
EPS (Annual)
$11.03
P/B
7.19
Rev/Employee
$668,877.84
$533,647.35
Loading...
Loading...
News
all
press releases
Johnson & Johnson (NYSE:JNJ) EVP Sells $1,508,287.83 in Stock
Johnson & Johnson (NYSE:JNJ - Get Free Report) EVP Vanessa Broadhurst sold 6,197 shares of the stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price...
MarketBeat·58m ago
News Placeholder
More News
News Placeholder
Johnson & Johnson (NYSE:JNJ) EVP Timothy Schmid Sells 22,623 Shares
Johnson & Johnson (NYSE:JNJ - Get Free Report) EVP Timothy Schmid sold 22,623 shares of Johnson & Johnson stock in a transaction on Wednesday, February 18th. The shares were sold at an average price...
MarketBeat·58m ago
News Placeholder
Top Medical Stocks To Follow Now - February 18th
Eli Lilly and Company, UnitedHealth Group, Johnson & Johnson, Avadel Pharmaceuticals, AbbVie, Thermo Fisher Scientific, and Medtronic are the seven Medical stocks to watch today, according to...
MarketBeat·8h ago
News Placeholder
Top Healthcare Stocks To Follow Today - February 18th
UnitedHealth Group, Johnson & Johnson, Medtronic, Intuitive Surgical, and Tempus AI are the five Healthcare stocks to watch today, according to MarketBeat's stock screener tool. Healthcare stocks are...
MarketBeat·8h ago
News Placeholder
Halozyme's Q4 Earnings Miss, Higher Royalties Drive Y/Y Revenues
HALO swings to Q4 loss on acquisition charge, but revenues surge 52%, fueled by royalties and product sales and top estimates.
Zacks·11h ago
News Placeholder
Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania
Johnson & Johnson (NYSE: JNJ) (the Company), healthcares leading, most comprehensive innovation powerhouse, today announced a more than $1 billion investment in a next generation cell therapy...
Business Wire·12h ago
News Placeholder
FDA Grants Breakthrough Status To Johnson & Johnson's Cancer Drug For Advanced Head and Neck Cancer
FDA grants Breakthrough Therapy status to Rybrevant for advanced cancer while Trellus Health extends IBD support contract.read more...
Benzinga·13h ago
News Placeholder
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Zacks·14h ago
News Placeholder
RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer
RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer RYBREVANT FASPRO (amivantamab and...
PR Newswire·15h ago
News Placeholder
Advisors Capital Management LLC Grows Position in Johnson & Johnson $JNJ
Advisors Capital Management LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 1.9% during the third quarter, according to its most recent filing with the SEC. The...
MarketBeat·17h ago
<
1
2
...
>

Latest JNJ News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.